Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ALDR

Alder Biopharmaceuticals (ALDR) Stock Price, News & Analysis

Alder Biopharmaceuticals logo

About Alder Biopharmaceuticals Stock (NASDAQ:ALDR)

Advanced Chart
Remove Ads

Key Stats

Today's Range
$18.88
$18.88
50-Day Range
$18.88
$18.88
52-Week Range
$8.39
$19.12
Volume
N/A
Average Volume
5.12 million shs
Market Capitalization
$1.58 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.

Remove Ads
Receive ALDR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Alder Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ALDR Stock News Headlines

Trump Allies Confirm Exec Order 14024 Triggers Dollar Collapse
Executive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth, your savings, and your retirement. When the dollar collapses, your savings could disappear overnight. With Trump threatening Russia with more sanctions, Russia is rushing to finalize their BRICS payment system aimed to destroy the U.S dollar.
See More Headlines

ALDR Stock Analysis - Frequently Asked Questions

Alder Biopharmaceuticals Inc (NASDAQ:ALDR) issued its earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.05) by $0.01.

Based on aggregate information from My MarketBeat watchlists, some other companies that Alder Biopharmaceuticals investors own include Bristol-Myers Squibb (BMY), (CPXX) (CPXX), NVIDIA (NVDA), Celldex Therapeutics (CLDX), Meta Platforms (META), Gilead Sciences (GILD) and Micron Technology (MU).

Company Calendar

Last Earnings
8/07/2018
Today
4/03/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ALDR
Fax
N/A
Employees
202
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-296,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.62 million
Price / Cash Flow
N/A
Book Value
$1.61 per share
Price / Book
11.73

Miscellaneous

Free Float
N/A
Market Cap
$1.58 billion
Optionable
Optionable
Beta
2.64
Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:ALDR) was last updated on 4/3/2025 by MarketBeat.com Staff
From Our Partners